Intelgenx Technologs (IGXT) 0.6550 $IGXT IntelGenx

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 2:49 PM

Intelgenx Technologs (IGXT) 0.6550 $IGXT

IntelGenx Reports Q1, 2015 Results and Provides Corporate Development Update
ACCESSWIRE - Thu May 14, 3:44PM CDT
SAINT LAURENT, QB / ACCESSWIRE / May 14, 2015 / IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company" or "IntelGenx"

today announced financial results for the three months ended March 31, 2015 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.
IGX.VN: 0.770 (-0.010)

IntelGenx Announces Management Changes
GlobeNewswire - Wed May 13, 4:39PM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

announced today that Mr. Paul Simmons has resigned as Chief Financial Officer ("CFO"

of IntelGenx and IntelGenx Corp, effective May 22, 2015.
IGX.VN: 0.770 (-0.010)

IntelGenx Confirms Execution of Lease and Construction Agreements
ACCESSWIRE - Tue May 05, 6:49AM CDT
SAINT LAURENT, QB / ACCESSWIRE / May 5, 2015 / IntelGenx Corp. (TSX VENTURE: IGX) (OTCQX: IGXT) ("IntelGenx", or the "Company"

today confirmed that it recently executed both the lease and construction agreements as anticipated, and as announced in IntelGenx' press release dated March 31, 2015.
IGX.VN: 0.770 (-0.010)

IntelGenx to Report 2015 First Quarter Update Call on May 15, 2015
GlobeNewswire - Mon May 04, 7:02AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its 2015 first quarter results for the period ended March 31, 2015, on May 14, 2015 at the close of the financial markets.
IGX.VN: 0.770 (-0.010)

IntelGenx Provides Q1, 2015 Update on Sales of Forfivo XL(R)
GlobeNewswire - Wed Apr 22, 7:15AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx", or the "Company"

today provided an update on the continued sales growth of Forfivo XL(R) in the USA.
IGX.VN: 0.770 (-0.010)

IntelGenx Announces Analyst Coverage Initiated by Singular Research
GlobeNewswire - Thu Apr 16, 7:05AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx"

today announced that Singular Research has initiated analyst coverage on IntelGenx.
IGX.VN: 0.770 (-0.010)

IntelGenx Founder, President and CEO Dr. Horst Zerbe Interviewed on Fox Business Network's "After the Bell"
GlobeNewswire - Fri Apr 10, 7:46AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx"

today announced its President and CEO Dr. Horst G. Zerbe, was a guest on FOX Business Network's After the Bell (weekdays 4-5PM/ET) on Thursday, April 9, 2015.
IGX.VN: 0.770 (-0.010)

IntelGenx Grants Stock Options
GlobeNewswire - Thu Apr 02, 11:14AM CDT
IntelGenx Technologies Corp. ("IntelGenx", or the "Company"

(TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2006 Stock Option Plan, as amended.
IGX.VN: 0.770 (-0.010)

IntelGenx Technologies' (IGXT) CEO Horst Zerbe on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 3:27PM CDT

IntelGenx Reports 2014 Annual Results and Provides Corporate Development Update
ACCESSWIRE - Tue Mar 31, 7:14AM CDT
SAINT LAURENT, QUEBEC / ACCESSWIRE / March 31, 2015 / IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx"

today announced financial results for its fiscal year ended December 31, 2014 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.
IGX.VN: 0.770 (-0.010)

IntelGenx to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
GlobeNewswire - Mon Mar 23, 7:02AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx", or the "Company"

a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its 2014 annual results for the period and full year ended December 31, 2014, on March 31, 2015 at the open of the financial markets.
IGX.VN: 0.770 (-0.010)

Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 44.44 (-0.38), AGN: 240.22 (+2.88), JNJ: 102.30 (+0.47), RDHL: 15.90 (+0.06), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22)

IntelGenx to Present at the 8th Annual OneMedForum
GlobeNewswire - Mon Jan 05, 7:25AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the 8 Annual OneMedForum to be held Monday, January 12, 2015 at the San Francisco Marriott Marquis. IntelGenx' presentation will take place January 12, 2015 at 10:40 A.M. Pacific Time.
IGX.VN: 0.770 (-0.010)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HANGCHA's AI-Fork Revolution: Bold Steps to 2030

Forklifts and the Future: A Fork in the Road for HANGCHA There's a movement happening, folks, and I don't mean in the usual stock ticker shift way. We're talking forklifts here—AI-powered, no less. HANGCHA Group, a name that may or may not roll off the tongue but sure makes waves in manufacturing, just held its 4th Global Dealers Conference in Hangzhou, China. If you're...

GrayMar’s Strategic Southeast Boost Could Reshape Market

GrayMar’s Big Southeast Step Alright, let’s face it—when a company like GrayMar Environmental Services decides to go on a shopping spree, it’s a signal worth heeding, especially if they’ve got their eyes on expanding their empire across the Southeast. This time, it’s not just another map pin but a strategic play with heft. GrayMar’s picked up six locations...

Jing'an District Drives Bold Investments at 2026 CIIE

Jing'an's Strategic Moves at 2026 CIIE When you hear "Shanghai," you probably think bright lights, bustling streets, and a city that never sleeps. Now narrow that down even further and you get Jing'an District—a place that's climbing the ladder not just in glitz, but in strategic moves that matter. This year, during the China International Import Expo (CIIE), Jing'an...

CREB Unlocks 8.50% APY Bonds for IRA Investors

CRET Broadens the Path to Fixed-Income Security If you're the type who gets a rash just thinking about stock market jitters, pay attention: Compound Real Estate Bonds (CREB) has cracked the door open a bit wider for your retirement peace of mind. They've teamed up with Equity Trust to offer their rock-solid 8.50% APY bonds through self-directed IRAs. That's right—these...

Munters Updates Financial Targets Amid Growth Plans

Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...

Legal Titans Join Las Vegas Economic Board: Strategic Moves

Legal Minds Stepping into Economic Turf in Las Vegas Out in the shimmering lights of Las Vegas, there's more than blackjack tables causing a stir. Joel Tasca from Greenberg Traurig, a law giant, now sits on the board of the Las Vegas Regional Economic Partnership (LVREP), marking a notable shift in local economic strategizing. Meanwhile, seasoned attorney Michael Bonner...

Minerva Foods' Profit Struggles Despite Revenue Growth

Setting the Stage: Minerva Foods' Latest Report Walking through the jungle of financial statements, few things are clear-cut. Minerva Foods handed out its latest report, stirring both optimism and concern among the suits at the table. Here's the brass tacks of it: a 9.5% boost in net revenue drumming up R$56.2 billion over twelve months. Sounds solid, huh? Yet, lurking...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

TruGreen Boosts Military Discount, Joins 'Military Makeover'

Lawn Care with a Heart Look, a lot of us grumble about mowing the grass, but TruGreen's turning lawn care into something with a little more meaning. This Veterans Day, they're not just about keeping those blades of grass in check. No, they're honoring the folks who've served this country. Their military discount just doubled from 10% to 20% through the end of November....

CGI Shines with Strong Q4, Announces Dividend Hike

CGI Records Impressive Fourth Quarter Growth Well, CGI's got reason to strut its stuff this time around. Clocked in with a fourth-quarter revenue of $4.15 billion - that's a nice 3.3% bump up year-over-year, if you leave the currency noise out of it, it's about 2.5%. The real kicker? Net earnings shot up 20.8%. In a world where everyone’s fighting over scraps, these...